... WhatsApp

New Drug Combination Offers Hope for People With Advanced Esophageal Cancer

You are here >> Home > Latest Updates > Esophagus Cancer Updates > New Drug…

Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma DOI 10.1016S1470-2045(25)00401-2

A new treatment may help people with advanced esophageal cancer live longer. The SKYSCRAPER-08 trial tested a mix of two cancer drugs, tiragolumab and atezolizumab, along with standard chemotherapy. The results are promising for patients whose cancer cannot be removed with surgery.

The study looked at over 460 people in Asia who had not received any previous treatment. One group received the two cancer drugs plus chemotherapy. The other group got only chemotherapy. The group that got the full mix lived about 4 months longer on average.

They also stayed free from cancer growth for longer—about 6 months compared to 5 months in the chemotherapy-only group.

Like most cancer treatments, side effects did happen. These included low white blood cell counts, infections, and some serious problems like pneumonia. But the risks were similar in both groups.

This research shows that adding tiragolumab and atezolizumab to chemotherapy can help control the cancer better and extend life. The results bring new hope to people facing a very hard-to-treat cancer.

Rate this post

Exclusive Health Tips and Updates

Dr Harsh Shah - GI & HPB Oncosurgeon in Ahmeadbad
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.